LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 36

Search options

  1. Article ; Online: Cytoprotective efficacy of amifostine against radiation- induced rectal toxicity: objective and subjective grading scales for radiomucositis.

    Kouloulias, Vassilis E / Kouvaris, John R

    Molecules (Basel, Switzerland)

    2008  Volume 13, Issue 4, Page(s) 892–903

    Abstract: Curative radiation therapy of pelvic malignancies, frequently results in dose limiting toxicities such as serous, mucoid, or more rarely, bloody diarrhea. Several studies have evaluated the cytoprotective effects of amifostine in preventing rectal ... ...

    Abstract Curative radiation therapy of pelvic malignancies, frequently results in dose limiting toxicities such as serous, mucoid, or more rarely, bloody diarrhea. Several studies have evaluated the cytoprotective effects of amifostine in preventing rectal mucositis associated with radiation treatment. We searched Medline for published comparative studies that evaluated the use of amifostine to reduce radiation-induced toxicity associated with pelvic irradiation. In ten studies there was an evidence-based cytoprotection (P less than 0.05)by amifostine. Although results are variable, current evidence suggests that amifostine may have a radioprotective effect in the rectal mucosa, particularly when administered intrarectally. Significant improvements were seen in both symptomatic and objective(rectosigmoidoscopy) end points. There is a need to conduct well-designed clinical trials with sufficient numbers of participants to confirm these findings together with a cost benefit study. Objective measurements using rectosigmoidoscopy are superior to subjective measures such as WHO or RTOG/EORTC toxicity grading scales.
    MeSH term(s) Amifostine/pharmacology ; Cytoprotection/drug effects ; Endpoint Determination ; Humans ; Radiation ; Rectal Diseases/chemically induced ; Treatment Outcome
    Chemical Substances Amifostine (M487QF2F4V)
    Language English
    Publishing date 2008-04-18
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 1413402-0
    ISSN 1420-3049 ; 1431-5165 ; 1420-3049
    ISSN (online) 1420-3049
    ISSN 1431-5165 ; 1420-3049
    DOI 10.3390/molecules13040892
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Bone Density as a Marker of Response to Radiotherapy in Bone Metastatic Lesions: A Review of the Published Data.

    Kouloulias, Vassilis / Liakouli, Zoi / Zygogianni, Anna / Mystakidou, Kyriaki / Kouvaris, John R

    International journal of molecular sciences

    2016  Volume 17, Issue 9

    Abstract: Metastases to the bone are presenting in a great percentage of patients with cancer, causing a variety of symptoms, affecting the quality of life and survival of patients. A multidisciplinary approach from different health providers is required for ... ...

    Abstract Metastases to the bone are presenting in a great percentage of patients with cancer, causing a variety of symptoms, affecting the quality of life and survival of patients. A multidisciplinary approach from different health providers is required for treatment, including radiation oncologists, medical oncologists and surgeons. The role of radiotherapy in the management of bone metastases has long been established through multiple randomized trials. The estimation of response to the therapy is subjective and is based on the palliation of the symptoms that the patients report. However, a quantification of the tumor burden and response to the treatment with the use of an objective method to measure those parameters is a clinical expectation in oncology. The change in bone density in affected areas (mainly lytic) after local radiotherapy, representing the cellular changes that have occurred, is a promising marker of response to treatment.
    MeSH term(s) Bone Density/physiology ; Bone Neoplasms/pathology ; Bone Neoplasms/secondary ; Humans ; Radiotherapy Dosage
    Language English
    Publishing date 2016-08-24
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2019364-6
    ISSN 1422-0067 ; 1422-0067 ; 1661-6596
    ISSN (online) 1422-0067
    ISSN 1422-0067 ; 1661-6596
    DOI 10.3390/ijms17091391
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Bone Density as a Marker of Response to Radiotherapy in Bone Metastatic Lesions

    Vassilis Kouloulias / Zoi Liakouli / Anna Zygogianni / Kyriaki Mystakidou / John R. Kouvaris

    International Journal of Molecular Sciences, Vol 17, Iss 9, p

    A Review of the Published Data

    2016  Volume 1391

    Abstract: Metastases to the bone are presenting in a great percentage of patients with cancer, causing a variety of symptoms, affecting the quality of life and survival of patients. A multidisciplinary approach from different health providers is required for ... ...

    Abstract Metastases to the bone are presenting in a great percentage of patients with cancer, causing a variety of symptoms, affecting the quality of life and survival of patients. A multidisciplinary approach from different health providers is required for treatment, including radiation oncologists, medical oncologists and surgeons. The role of radiotherapy in the management of bone metastases has long been established through multiple randomized trials. The estimation of response to the therapy is subjective and is based on the palliation of the symptoms that the patients report. However, a quantification of the tumor burden and response to the treatment with the use of an objective method to measure those parameters is a clinical expectation in oncology. The change in bone density in affected areas (mainly lytic) after local radiotherapy, representing the cellular changes that have occurred, is a promising marker of response to treatment.
    Keywords bone metastasis ; radiotherapy ; bone density ; Biology (General) ; QH301-705.5 ; Chemistry ; QD1-999
    Subject code 616
    Language English
    Publishing date 2016-08-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  4. Article ; Online: Bilateral primary breast Burkitt's lymphoma.

    Zygogianni, Anna G / Kokkakis, John / Antypas, Christos / Armpilia, Christina / Kouloulias, Vassilis / Kouvaris, John R

    The breast journal

    2010  Volume 16, Issue 6, Page(s) 655–656

    MeSH term(s) Adult ; Breast Neoplasms/pathology ; Breast Neoplasms/radiotherapy ; Burkitt Lymphoma/pathology ; Burkitt Lymphoma/radiotherapy ; Female ; Humans
    Language English
    Publishing date 2010-11
    Publishing country United States
    Document type Case Reports ; Journal Article
    ZDB-ID 1289960-4
    ISSN 1524-4741 ; 1075-122X
    ISSN (online) 1524-4741
    ISSN 1075-122X
    DOI 10.1111/j.1524-4741.2010.00985.x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: Amifostine: the first selective-target and broad-spectrum radioprotector.

    Kouvaris, John R / Kouloulias, Vassilis E / Vlahos, Lampros J

    The oncologist

    2007  Volume 12, Issue 6, Page(s) 738–747

    Abstract: After several decades of preclinical and clinical research, the first approved radioprotective drug, amifostine, is being used in clinical practice. Amifostine has been shown to specifically protect normal tissues from damage caused by radiation and ... ...

    Abstract After several decades of preclinical and clinical research, the first approved radioprotective drug, amifostine, is being used in clinical practice. Amifostine has been shown to specifically protect normal tissues from damage caused by radiation and chemotherapy. An inactive prodrug, amifostine is converted to an active thiol by dephosphorylation by alkaline phosphatase in the normal endothelium. The hypovascularity and acidity of the tumor environment and the differential expression of alkaline phosphatase in normal and neoplastic tissues contribute to its cytoprotective selectivity. The cytoprotective mechanism of amifostine is complicated, involving free-radical scavenging, DNA protection and repair acceleration, and induction of cellular hypoxia. The U.S. Food and Drug Administration has approved the i.v. use of amifostine to reduce the cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer and to reduce the incidence of moderate to severe xerostomia in patients undergoing postoperative radiation treatment for head and neck cancer, where the radiation port includes a substantial portion of the parotid glands. Nonetheless, amifostine has potential applications in many other oncologic settings. Novel schedules and routes of administration are under investigation and may further simplify the use of amifostine, reduce any undesired effects, and considerably broaden its applications. This review summarizes the clinical experience with amifostine and provides insight into future clinical directions.
    MeSH term(s) Amifostine/pharmacokinetics ; Amifostine/therapeutic use ; Humans ; Mucositis/etiology ; Mucositis/prevention & control ; Neoplasms/drug therapy ; Neoplasms/radiotherapy ; Radiation-Protective Agents/pharmacokinetics ; Radiation-Protective Agents/therapeutic use ; Radiotherapy/adverse effects ; Treatment Outcome ; Xerostomia/etiology ; Xerostomia/prevention & control
    Chemical Substances Radiation-Protective Agents ; Amifostine (M487QF2F4V)
    Language English
    Publishing date 2007-06
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 1409038-7
    ISSN 1083-7159
    ISSN 1083-7159
    DOI 10.1634/theoncologist.12-6-738
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Irradiation Toxicity and Inflammatory Bowel Diseases (IBD): Review.

    Tolia, Maria / Zygogianni, Anna / Kouvaris, John R / Tsoukalas, Nikolaos / Kokakis, Ioannis / Kyrgias, George / Mystakidou, Kyriaki / Kouloulias, Vasileios

    Reviews on recent clinical trials

    2014  Volume 9, Issue 1, Page(s) 31–36

    Abstract: Background/aim: The evaluation of radiotherapy toxicity in oncologic IBD patients. Defining the optimal patient and treatment factors that would be able to reduce the risk to organs.: Materials and methods: A review of all published radiotherapy ... ...

    Abstract Background/aim: The evaluation of radiotherapy toxicity in oncologic IBD patients. Defining the optimal patient and treatment factors that would be able to reduce the risk to organs.
    Materials and methods: A review of all published radiotherapy trials was performed to identify the clinical and treatment factors of inflammatory bowel disease's patients treated for different solid tumors.
    Results: Overall, acute (Grade ≥ 3) gastrointestinal complications attributable to RT ranged between 20-21% of the treated patients. A late Grade ≥ 3 gastrointestinal toxicity was developed in a range between 8-29%.
    Conclusion: A special attention should be given to the description of IBD location, activity status, concurrent chemotherapy, irradiation dose and technique, in order to minimize post-irradiation morbidity. It is not easy to distinguish late morbidity attributable to radiotherapy due to the IBD itself.
    MeSH term(s) Clinical Trials as Topic ; Humans ; Inflammatory Bowel Diseases/complications ; Neoplasms/complications ; Neoplasms/radiotherapy ; Radiation Injuries/etiology
    Language English
    Publishing date 2014-04-15
    Publishing country United Arab Emirates
    Document type Journal Article ; Review
    ZDB-ID 2251879-4
    ISSN 1876-1038 ; 1574-8871
    ISSN (online) 1876-1038
    ISSN 1574-8871
    DOI 10.2174/1574887109666140423123845
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Hypofractionated accelerated irradiation for stage I-II breast carcinoma: a phase II study.

    Zygogianni, Anna G / Kouvaris, John R / Kouloulias, Vassilis / Armpilia, Christina / Antypas, Christos / Vlachos, Lambros

    The breast journal

    2010  Volume 16, Issue 3, Page(s) 337–338

    MeSH term(s) Breast Neoplasms/pathology ; Breast Neoplasms/radiotherapy ; Dose Fractionation ; Female ; Humans ; Neoplasm Staging
    Language English
    Publishing date 2010-05
    Publishing country United States
    Document type Clinical Trial, Phase II ; Letter
    ZDB-ID 1289960-4
    ISSN 1524-4741 ; 1075-122X
    ISSN (online) 1524-4741
    ISSN 1075-122X
    DOI 10.1111/j.1524-4741.2010.00913.x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Cytoprotective Efficacy of Amifostine Against Radiation- Induced Rectal Toxicity

    John R. Kouvaris / Vassilis E. Kouloulias

    Molecules, Vol 13, Iss 4, Pp 892-

    Objective and Subjective Grading Scales for Radiomucositis

    2008  Volume 903

    Abstract: Curative radiation therapy of pelvic malignancies, frequently results in doselimitingtoxicities such as serous, mucoid, or more rarely, bloody diarrhea. Several studieshave evaluated the cytoprotective effects of amifostine in preventing rectal ... ...

    Abstract Curative radiation therapy of pelvic malignancies, frequently results in doselimitingtoxicities such as serous, mucoid, or more rarely, bloody diarrhea. Several studieshave evaluated the cytoprotective effects of amifostine in preventing rectal mucositisassociated with radiation treatment. We searched Medline for published comparativestudies that evaluated the use of amifostine to reduce radiation-induced toxicity associatedwith pelvic irradiation. In ten studies there was an evidence-based cytoprotection (P less than 0.05)by amifostine. Although results are variable, current evidence suggests that amifostine mayhave a radioprotective effect in the rectal mucosa, particularly when administeredintrarectally. Significant improvements were seen in both symptomatic and objective(rectosigmoidoscopy) end points. There is a need to conduct well-designed clinical trialswith sufficient numbers of participants to confirm these findings together with a costbenefitstudy. Objective measurements using rectosigmoidoscopy are superior tosubjective measures such as WHO or RTOG/EORTC toxicity grading scales.
    Keywords Cytoprotection ; radiotherapy ; rectum ; mucositis ; toxicity ; amifostine ; Organic chemistry ; QD241-441
    Language English
    Publishing date 2008-04-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  9. Article ; Online: Femoral muscle metastasis from gastric carcinoma.

    Gogou, Pinelopi V / Polydorou, Andreas / Papacharalampous, Xenophon N / Kondi-Paphiti, Agatha / Balafouta, Myrsini J / Gennatas, Constantinos S / Kouvaris, John R

    The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology

    2012  Volume 23, Issue 5, Page(s) 611–612

    MeSH term(s) Adenocarcinoma/diagnosis ; Adenocarcinoma/secondary ; Adenocarcinoma/surgery ; Biopsy ; Diagnosis, Differential ; Gastrectomy ; Humans ; Leg ; Magnetic Resonance Imaging ; Male ; Muscle Neoplasms/diagnosis ; Muscle Neoplasms/secondary ; Neoplasm Staging ; Stomach Neoplasms/pathology ; Stomach Neoplasms/surgery
    Language English
    Publishing date 2012-11-17
    Publishing country Turkey
    Document type Case Reports ; Letter
    ZDB-ID 1340275-4
    ISSN 2148-5607 ; 1300-4948
    ISSN (online) 2148-5607
    ISSN 1300-4948
    DOI 10.4318/tjg.2012.0394
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Prognostic Significance of Serum Inflammatory Response Markers in Newly Diagnosed Non-Small Cell Lung Cancer before Chemoirradiation.

    Tolia, Maria / Tsoukalas, Nikolaos / Kyrgias, George / Mosa, Eftychia / Maras, Apostolos / Kokakis, Ioannis / Liakouli, Zoi / Kouvaris, John R / Liaskonis, Konstantinos / Charalampakis, Nikolaos / Pistevou-Gombaki, Kyriaki / Kelekis, Nikolaos / Kouloulias, Vassilis

    BioMed research international

    2015  Volume 2015, Page(s) 485732

    Abstract: Purpose: To identify whether the serum's baseline C-reactive protein (CRP) and albumin (Alb) levels related to clinicopathological parameters and overall survival (OS) in non-small cell lung cancer (NSCLC).: Methods: In total, 100 consecutive ... ...

    Abstract Purpose: To identify whether the serum's baseline C-reactive protein (CRP) and albumin (Alb) levels related to clinicopathological parameters and overall survival (OS) in non-small cell lung cancer (NSCLC).
    Methods: In total, 100 consecutive patients (mean age = 68.38 ± 10.85 years) that underwent chemoradiotherapy were studied. Measurements of CRP and Alb were performed before any treatment.
    Results: Serum CRP levels were significantly associated with histological grade (P < 0.001), TNM stage (P < 0.001), PS (P = 0.009), and Alb (P < 0.001). Additionally CRP and Alb levels were found significantly associated with overall survival in univariate analysis (log-rank test, P < 0.001 and P = 0.002, resp.) and CRP remained significant after controlling for age, alcohol, performance status, and TNM stage, whereas albumin showed a borderline effect on the hazard rate (P = 0.052).
    Conclusions: CRP and Alb are both promising biomarkers in identification of NSCLC patients with poor prognosis and form a possible target for intensifying their therapies.
    MeSH term(s) Adult ; Aged ; Aged, 80 and over ; Biomarkers, Tumor/blood ; C-Reactive Protein/metabolism ; Carcinoma, Non-Small-Cell Lung/blood ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/pathology ; Carcinoma, Non-Small-Cell Lung/radiotherapy ; Cell Proliferation/drug effects ; Cell Proliferation/radiation effects ; Chemoradiotherapy ; Female ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Prognosis ; Radiotherapy, Conformal ; Serum Albumin/metabolism
    Chemical Substances Biomarkers, Tumor ; Serum Albumin ; C-Reactive Protein (9007-41-4)
    Language English
    Publishing date 2015-08-03
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2698540-8
    ISSN 2314-6141 ; 2314-6133
    ISSN (online) 2314-6141
    ISSN 2314-6133
    DOI 10.1155/2015/485732
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top